{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:24Z","timestamp":1790830824701,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance commonly develops after treatment with first- or second-generation EGFR-TKIs. Aumolertinib, a third-generation EGFR-TKI, has demonstrated efficacy in tumors harboring the EGFR exon 20 T790M resistance mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 57-year-old man with stage IIIA lung adenocarcinoma and a history of hypertension and long-term smoking underwent thoracoscopic lobectomy with intrapulmonary lymph node dissection. Postoperative molecular testing identified an EGFR exon 19 deletion, and adjuvant oral icotinib (375\u00a0mg\/d) was initiated. After treatment discontinuation, disease recurrence was detected on PET-CT involving the right hilar lymph nodes and a right pleural\/subpleural lesion, which was confirmed by biopsy. Repeat molecular testing revealed concurrent EGFR exon 19 deletion and EGFR exon 20 T790M mutation. After 1 month of aumolertinib treatment, the target lesion decreased in size from 24 to 23\u00a0mm and was assessed as stable disease according to RECIST version 1.1, whereas the serum CEA level decreased from 24.19 to 4.35\u00a0ng\/mL, indicating early disease control with a biochemical response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates early disease control and a biochemical response to aumolertinib treatment in recurrent NSCLC with an EGFR exon 20 T790M mutation detected at recurrence. It also highlights the importance of repeat molecular testing to guide therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1878253","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:46:26Z","timestamp":1790829986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenyu","family":"Niu","sequence":"first","affiliation":[{"name":"Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou Normal University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Huzhou Central Hospital, The Affiliated Central Hospital of Huzhou Normal University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhong","family":"Xu","sequence":"additional","affiliation":[{"name":"Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibin","family":"Shen","sequence":"additional","affiliation":[{"name":"Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University","place":["Huzhou, Zhejiang, China"]},{"name":"Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University","place":["Huzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e95897","DOI":"10.1371\/journal.pone.0095897","article-title":"Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105583","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II\u2013IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.21037\/tlcr-21-649","article-title":"Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations","volume":"10","author":"He","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3779\/j.issn.1009-3419.2015.12.04","article-title":"Clinical observation of icotinib hydrochloride for advanced non-small cell lung cancer patients with EGFR status identified","volume":"18","author":"Li","year":"2015","journal-title":"Zhongguo Fei Ai Za Zhi = Chin. J. Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.jtho.2018.08.618","article-title":"P1.01-62 the third generation irreversible EGFR inhibitor HS-10296 in advanced non-small cell lung cancer patients","volume":"13","author":"Lu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.jtho.2019.08.413","article-title":"OA02.03 the third generation EGFR inhibitor (EGFR-TKI) HS-10296 in advanced NSCLC patients with resistance to first generation EGFR-TKI","volume":"14","author":"Lu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101565","DOI":"10.1016\/j.esmoop.2023.101565","article-title":"Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)\u2606","volume":"8","author":"Lv","year":"2023","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3779\/j.issn.1009-3419.2013.05.05","article-title":"Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride","volume":"16","author":"Nong","year":"2013","journal-title":"Zhongguo Fei Ai Za Zhi = Chin. J. Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CMAR.S138643","article-title":"Comparison of Gefitinib as First- and Second-Line Therapy for Advanced Lung Adenocarcinoma Patients with Positive Exon 21 or 19 Del Epidermal Growth Factor Receptor Mutation","volume":"9","author":"Patel","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/oncolo\/oyac022","article-title":"Tyrosine kinase inhibitor activity in patients with NSCLC harboring uncommon EGFR mutations: a retrospective international cohort study (UpSwinG)","volume":"27","author":"Popat","year":"2022","journal-title":"Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"\u201cNon\u2013Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.\u201d journal of the national comprehensive cancer network","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J. Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2147\/OTT.S93823","article-title":"Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to First- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol. EGFR Mutant Non-small-cell Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3779\/j.issn.1009-3419.2015.06.07","article-title":"Comparison of the Efficacy and Safety of Icotinib with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer","volume":"18","author":"Yao","year":"2015","journal-title":"Zhongguo Fei Ai Za Zhi = Chin. J. Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3892\/etm.2020.8612","article-title":"Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups","volume":"19","author":"Zhang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(25)00643-6","article-title":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","volume":"27","author":"Zhang","year":"2026","journal-title":"Lancet Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:46:42Z","timestamp":1790830002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1878253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1878253"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1878253","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1878253"}}